ArticleBMC infectious diseases2025
First report of widespread kdr-L995F pyrethroid-resistant An. arabiensis and Temporal trends of pyrethroid resistance in urban Ilorin, Kwara State, Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pyrethroid-resistance in Anopheles gambiae s.l (Culicidae) populations from the Sudan Savannah ecoregion in Nigeria is partly mediated by knockdown mutation.BMC research notes · 2026Article
- Maternal and cross-stage effects of Metarhizium pingshaense fungal infection on the malaria mosquito Anopheles coluzzii life-history.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEffectiveness of currently deployed insecticide-based malaria vector control measures depends on continuous insecticide resistance monitoring and management. Urban malaria is becoming a serious health problem in Africa partly due to vector resistance in urban areas. To provide insecticide resistance trends information for effective resistance management, this study assessed insecticide susceptibility status and occurrence of knock down resistance mutation in Anopheles mosquitoes from urban Ilorin, Nigeria in two different years.
methodsMalaria vectors in urban Ilorin were assayed for susceptibility to WHO-recommended insecticides in 2017 and 2020 using WHO test kits. Sub-sets of exposed An. gambiae s.l. mosquitoes were PCR-assayed for sibling species and knock down resistance (kdr) mutation detection.
resultsFull mosquito susceptibility (98–100% mortality; Niger and Baruba) and suspected resistance (95–97% mortality; Shao garage and Edun) to alphacypermethrin were recorded in 2017. Significantly (p ≤ 0.010) reduced mosquito mortalities indicating increased alphacypermethrin resistance were recorded in 2020. Permethrin, lambda-cyhalothrin and DDT resistance increased significantly (p ≤ 0.03) from 2017 (42–89%) to 2020 (5.8–58%) but not deltamethrin (p ≥ 0.086). Mosquitoes tested were mostly susceptible to bendiocarb and pirimiphos-methyl. The kdr-L995F detected increased from 15 to 20% for An. arabiensis, 24–36% for An. gambiae and 0–18% for An. coluzzii from 2017 to 2020. For both 2017 and 2020, most of the pyrethroid resistant (≥ 80%) and susceptible (≥ 75%) mosquitoes from each site were identified as An. arabiensis.
conclusionsThis study presents a first report on widespread occurrence of kdr-L995F mutation in An. arabiensis mosquito populations in urban Ilorin, Kwara State, Nigeria. The report of pyrethroid-resistant An. arabiensis prevalence in urban Ilorin triggered the switch from pyrethroid only to dual active ingredient ITN distribution in the city since 2020. Extension of dry season periods due to climate change may drive more preponderance of An. arabiensis in the study area. Therefore, the implementation of supplementary vector control measures targeted at An. arabiensis is required in this locality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.